Intravenous Nesiritide, a Natriuretic Peptide, in the Treatment of Decompensated Congestive Heart Failure
Wilson S. Colucci(Cornell University), Thierry H. LeJemtel(University of Maryland, Baltimore), Chang‐seng Liang(University of Rochester Medical Center), Uri Elkayam(University of Southern California), Matthew Neibaur(Jacksonville University), William T. Abraham(Lung Institute), Michael M. Givertz(Brigham and Women's Hospital), Lynne E. Wagoner(University of Cincinnati), Allen D. Johnson(Scripps Health), W. Herbert Haught, Darlene P. Horton(Napo Pharmaceuticals (United States)), Robert C. Bourge(University of Alabama at Birmingham)
Cited by 908
Related Papers
Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
|American Heart Journal|2005|2.1k
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
|The Lancet|2009|2.1k
Targeted Anticytokine Therapy in Patients With Chronic Heart Failure
|Circulation|2004|1.2k
Aliskiren, ALTITUDE, and the Implications for ATMOSPHERE
|European Journal of Heart Failure|2012|1.1k
Mitochondrial function as a therapeutic target in heart failure
|Nature Reviews Cardiology|2016|786